Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Study reveals how Lyme disease spreads through the body
Lyme disease bacteria
Lyme disease bacteria (Borrelia burgdorferi) spreads through the body by clinging to the lining of blood vessels.

Cell-imaging approach offers new insights

Research by the University of Toronto has revealed how Lyme disease bacteria spreads through the body.

Published in the journal Cell Reports, the study found that a special adhesion protein called BBK32 helps Lyme disease bacteria (Borrelia burgdorferi) cling onto and move along the inside lining of blood vessels.  

"It's likely that this property helps the bacteria get to sites where they might be able to persist longer, and this property might therefore make it harder to treat infections caused by these bacteria," explains first author Rhodaba Ebady.

In the study, the team developed a live-imaging-cell based system that provides both molecular and biomechanical insights into how bacteria travels throughout the body.

Using genetically modified strains of Borrelia burgdorferi, the team watched through a microscope as the bacteria - marked with fluorescent green protein - moved across cells in real time.

Their findings suggest that drugs targeting BBK32 could help to prevent or slow down the spread of Lyme disease bacteria to joints, the heart and nervous system.

This would eliminate or reduce the severity of symptoms like heart inflammation, arthritis, facial paralysis and nerve pain, the researchers say.

Furthermore, because BBK32-like proteins are produced by pathogens like Staphylococcus aureus and Streptococcus pyogenes, the researchers believe their findings may also be relevant to other serious conditions, like pneumonia and inflammation affecting the heart.

Looking ahead, the team hope to identify endothelial receptors that BBK32 interact with, assess the biomechanical role of bacterial flagella in vascular interactions, and try to determine how bacteria target specific endothelia associated with different tissues.

More broadly, the team hope their cell-imaging approach could be used to study how other pathogens spread throughout the body.

Image (C) Jamice Haney Carr, Claudia Molins, USCDCP 

Become a member or log in to add this story to your CPD history

Applications open for MMI research grants

News Story 1
 RCVS' Mind Matters Initiative (MMI) has launched round two of its veterinary mental health research grants.

Researchers have until 11.59pm on Wednesday, 28 May 2025 to apply for a grant for research which reflects MMI's 2025 focus areas.

Only one Impact Grant was awarded last year, and so this year there are two Discovery Grants and one Impact Grants available. Each Discovery Grant is worth £5,000 and the Impact Grant is worth £15,000.

For more information or to apply, email researchgrants@rcvs.org.uk to contact the MMI team.

 

Click here for more...
News Shorts
Wales licenses Bluetongue vaccines for voluntary use

The Welsh government has approved three Bluetongue vaccines for emergency use in Wales.

From 1 March an online general licence will become available for the vaccines' use. They will then be obtainable on prescription and can be sold by veterinary practices.

After appropriate guidance, livestock keepers will be permitted to administer the vaccines themselves. The vaccines must be prescribed by a veterinary surgeon and detailed vaccination records must be kept for five years.

The decision comes as Bluetongue virus (BTV-3) continues to spread across England. The three vaccines are already licensed for use in England.

Richard Irvine, CVO for Wales, said: "This decision to licence these vaccines was informed by our recent risk assessment indicating that Wales is now at high risk of experiencing an incursion of Bluetongue this year.

"Our primary aim is to keep Bluetongue out of Wales through biosecurity, vigilance and safe sourcing of livestock."